Implications of Vancomycin Degradation Products on Therapeutic Drug Monitoring in Patients with End‐Stage Renal Disease

In renally impaired patients, vancomycin concentrations typically are maintained at body temperature for extended periods of time due to the drug's prolonged half‐life. Both time and increased temperature potentiate production of vancomycin crystalline degradation products (CDP‐1). Commercially available vancomycin assays, such as fluorescence polarization immunoassay (FPI) and radioimmunoassay, cross‐react with CDP‐1 isomers. Overestimation of vancomycin concentrations by 40–53% due to cross‐reactivity of CDP‐1 with active factor B vancomycin occurs with FPI. As FPI is the most common method of analyzing serum vancomycin, clinicians must be aware of its potential shortcomings and be prepared to alter vancomycin dosages in renally impaired patients. The possibility of adverse affects due to elevated concentrations of CDP‐1 or therapeutic failures due to subtherapeutic levels of factor B vancomycin cannot be excluded.

[1]  D. Thompson,et al.  Historical Yearly Usage of Vancomycin , 1998, Antimicrobial Agents and Chemotherapy.

[2]  T. Johns,et al.  Laboratory guidelines for monitoring of antimicrobial drugs , 1998 .

[3]  W. Petros,et al.  New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease. , 1998, Therapeutic Drug Monitoring.

[4]  I. Ieiri,et al.  Instability of standard calibrators may be involved in overestimating vancomycin concentrations determined by fluorescence polarization immunoassay. , 1996, Therapeutic drug monitoring.

[5]  N. Saunders.  Vancomycin administration and monitoring reappraisal. , 1995, The Journal of antimicrobial chemotherapy.

[6]  R. Moellering.  Monitoring serum vancomycin levels: climbing the mountain because it is there? , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  P. Lietman,et al.  Serum vancomycin concentrations: reappraisal of their clinical value. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  B. Ackerman,et al.  Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response , 1992, Antimicrobial Agents and Chemotherapy.

[9]  G. Hortin,et al.  Cross-reactivity of a vancomycin degradation product in three immunoassays of vancomycin. , 1991, Clinical chemistry.

[10]  K. Rodvold,et al.  An Updated Comparison of Drug Dosing Methods , 1991, Clinical pharmacokinetics.

[11]  K. Rodvold,et al.  An Updated Comparison of Drug Dosing Methods , 1991, Clinical pharmacokinetics.

[12]  M. Hu,et al.  Measurement of Vancomycin in Renally Impaired Patient Samples Using a New High‐Performance Liquid Chromatography Method with Vitamin B12 Internal Standard: Comparison of High‐Performance Liquid Chromatography, Emit, and Fluorescence Polarization Immunoassay Methods , 1990, Therapeutic drug monitoring.

[13]  W. Peetermans,et al.  Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection , 1990, Antimicrobial Agents and Chemotherapy.

[14]  J. M. Lanao,et al.  Effect of renal impairment on distribution of ofloxacin. , 1990 .

[15]  K. Chan,et al.  Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. , 1989, Therapeutic drug monitoring.

[16]  G. Horowitz,et al.  Clinical performance of the EMIT vancomycin assay. , 1989, Clinical chemistry.

[17]  R. Finch,et al.  The in-vitro degradation at 37°C of vancomycin in serum, CAPD fluid and phosphate-buffered saline , 1988 .

[18]  J. Rotschafer,et al.  Vancomycin pharmacokinetics in patients with various degrees of renal function , 1988, Antimicrobial Agents and Chemotherapy.

[19]  J. Flandrois,et al.  Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus , 1988, Antimicrobial Agents and Chemotherapy.

[20]  G. Morse,et al.  Overestimation of Vancomycin Concentrations Utilizing Fluorescence Polarization Immunoassay in Patients on Peritoneal Dialysis , 1987, Therapeutic drug monitoring.

[21]  P. Murray,et al.  Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay , 1984, Journal of clinical microbiology.

[22]  R. Hay,et al.  Laboratory methods for flucytosine (5-fluorocytosine) , 1984 .

[23]  C. Harris,et al.  VANCOMYCIN: STRUCTURE AND TRANSFORMATION TO CDP-I , 1983 .

[24]  J. Rotschafer,et al.  Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations , 1982, Antimicrobial Agents and Chemotherapy.

[25]  D J Greenblatt,et al.  Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. , 1981, Annals of internal medicine.

[26]  J. Geraci,et al.  Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report. , 1958, Proceedings of the staff meetings. Mayo Clinic.

[27]  M. K. Scott,et al.  Falsely elevated serum vancomycin concentrations in hemodialysis patients. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  J. Rotschafer,et al.  Routine monitoring of serum vancomycin concentrations: can waiting be justified? , 1987, Clinical pharmacy.

[29]  R. Griffith.  Vancomycin use--an historical review. , 1984, The Journal of antimicrobial chemotherapy.

[30]  F. J. Marshall.  STRUCTURE STUDIES ON VANCOMYCIN. , 1965, Journal of medicinal chemistry.